Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00579514 · ClinicalTrials.gov registry record · NA

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

A NA study of Breast Cancer and Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
21,081
Enrollment target
1
Study location

NCT00579514: Active NA study of Breast Cancer and Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00579514 is a NA study of Breast Cancer and Prostate Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 21,081 participants, above the 2,786-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (657% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00579514, a NA study of Breast Cancer and Prostate Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
21,081 participants
Enrollment target
1
Study location

Study Summary

The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid organs, and head and neck. This is an exploratory study designed to generate hypotheses for further research.

Interventions

  • GENETIC PCR/PCR/LDR Strategy

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 21,081 participants
Start Date 2000-03
Est. Completion 2026-03
Phase NA
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT00579514 still lists

NCT00579514 is an interventional study that assigns participants to a tested intervention. Its 21,081 participants enrollment target places it among the larger protocols in the corpus, above the 2,786-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (657% higher).

The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which PCR/PCR/LDR Strategy is the first listed.

NCT00579514 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00579514 about?

NCT00579514 is a clinical study titled "Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients". The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid organs, and head and neck. This is an exploratory study designed to gen...

What is the current status of trial NCT00579514?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 21,081 participants. The study started on 2000-03. Estimated completion is 2026-03.

What conditions does trial NCT00579514 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer, Bladder Cancer.

What interventions are being tested in trial NCT00579514?

The interventions under investigation include: PCR/PCR/LDR Strategy (GENETIC).

Who is sponsoring clinical trial NCT00579514?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00579514 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00579514's enrollment target sits among peer trials

21,081 10th of 1224 higher than 1,215 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07213531 · 21,000 participants

    Enhanced Valves Interventions and Safe AI Generated End Results

  • NCT06047041 · 21,350 participants · NA

    Implementation Supports for Improving Identification and Delivery of School-based Mental Health Supports for Middle Schools Students

  • NCT06062342 · 20,400 participants · NA

    Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities

  • NCT05832307 · 22,000 participants · NA

    The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00579514, the US trial registry maintained by the National Library of Medicine. NCT00579514 (large enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.